3 Pharmaceutical Formulations Maker, Gold Jewellery Manufacturer and Personal Care Company Stocks With a Strong Future Roadmap: Innova Captab, Sky Gold and Diamonds and Marico

Innova Captab, Sky Gold and Diamonds and Marico: ROE of 12.9% to 41.9% and FY22 to FY26 revenue CAGR of 9.5% to 67.9%. Prices as of 11 Nov 2026.

Updated: 12 Nov 2026 • 1:15 pm

Posted by:

3 Pharmaceutical Formulations Maker, Gold Jewellery Manufacturer and Personal Care Company Stocks With a Strong Future Roadmap: Innova Captab, Sky Gold and Diamonds and Marico

Quick Answer

The three pharma, gold jewellery and hair care stocks to watch are Innova Captab, Sky Gold and Diamonds and Marico. Their return on equity ranges from 12.9% to 41.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 67.9%. Marico has the highest return on equity at 41.9%, while Sky Gold and Diamonds has the fastest revenue growth at 67.9% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.

Pharma, gold jewellery and hair care stocks give investors a way to track businesses that sit close to everyday demand in India. Innova Captab, Sky Gold and Diamonds and Marico cover a pharmaceutical formulations maker, a gold jewellery manufacturer and a personal care company.

This list covers three pharma, gold jewellery and hair care stocks with complete current figures: Innova Captab, Sky Gold and Diamonds and Marico. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Pharma, Gold Jewellery and Hair Care Stocks?

Pharma, gold jewellery and hair care stocks are listed companies that make tablets, capsules and syrups for Indian and global drug firms, manufacture gold and diamond jewellery for retailers, and sell hair oils, edible oils and personal care products. Their earnings depend on prescription demand, jewellery orders and household spending.

Pharma, Gold Jewellery and Hair Care Stocks at a Glance

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE (%)	D/E
Innova Captab	1,092	5,736	37.2	36.0	12.9	0.32
Sky Gold and Diamonds	983.4	14,483	35.7	44.2	23.0	0.73
Marico	925	101,286	51.9	33.9	41.9	0.13

On valuation, Sky Gold and Diamonds trades at a P/E below the industry P/E, while Innova Captab and Marico trade above it, which reflects the growth the market already expects. Readers comparing pharma, gold jewellery and hair care stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma, Gold Jewellery and Hair Care Stocks Have a Strong Roadmap in India?

Pharma, gold jewellery and hair care stocks have a strong roadmap in India because steady demand for quality medicines, a shift to organised jewellery and rising household spending on personal care keep widening the market for these companies.

Pharma formulations. Drug firms outsource tablets and capsules.
Gold jewellery. Organised retailers source from large makers.
Personal care. Households buy trusted daily brands.

Why Innova Captab Features Among These Pharma, Gold Jewellery and Hair Care Stocks

Among the pharma, gold jewellery and hair care stocks on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Why Sky Gold and Diamonds Features Among These Pharma, Gold Jewellery and Hair Care Stocks

Among the tablet maker, ornament maker and coconut oil shares on this list, Sky Gold and Diamonds is a Navi Mumbai-based manufacturer of gold and diamond jewellery that supplies leading jewellery retail chains and also serves export customers.

The company has a return on equity of 23.0%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 14,483 crore. The stock trades at a P/E of 35.7, below the industry P/E of 44.2.

Revenue rose from Rs 796 crore in FY22 to Rs 6,331 crore in FY26, a compound annual growth rate of 67.9%. Net profit grew from Rs 133 crore in FY25 to Rs 282 crore in FY26, a rise of 112.4%.

Roadmap: The company is growing its supply to organised jewellery retailers as the market shifts toward branded jewellery. Wide design capability and large-scale manufacturing support repeat orders.

What to watch: Track retailer order flow, gold price movements and festive season demand.

Why Marico Features Among These Pharma, Gold Jewellery and Hair Care Stocks

Among the three companies on this list, Marico is a consumer products company that sells Parachute coconut oil, Saffola edible oils and foods, Nihar and Set Wet, along with a growing digital-first brand portfolio, in India and overseas.

Revenue rose from Rs 9,610 crore in FY22 to Rs 13,815 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 1,255 crore in FY22 to Rs 1,813 crore in FY26, which works out to a compound annual growth rate of 9.6%.

In the June 2026 quarter, revenue grew 22.2% year on year to Rs 4,005 crore, while net profit rose 27.1% to Rs 652 crore. The company has a return on equity of 41.9%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 101,286 crore. The stock trades at a P/E of 51.9, above the industry P/E of 33.9.

Roadmap: The company is widening its foods and premium personal care portfolio while strengthening its core brands. Marico also sells in Bangladesh, Vietnam and Africa, which adds international growth, and its brands command strong market share.

What to watch: Watch the growth of the foods and premium personal care categories and copra price trends.

Innova Captab vs Sky Gold and Diamonds vs Marico on Key Financials

The table below sets the three pharma, gold jewellery and hair care stocks side by side on revenue, profit and margin, using reported figures.

Company	FY22 Revenue (Rs Cr)	FY26 Revenue (Rs Cr)	Revenue CAGR (FY22-FY26)	FY26 Net Profit (Rs Cr)	FY26 Net Margin
Innova Captab	803	1,637	19.5%	141	8.6%
Sky Gold and Diamonds	796	6,331	67.9%	282	4.5%
Marico	9,610	13,815	9.5%	1,813	13.1%

Marico posts the highest return on equity in this group at 41.9%. Marico has the largest FY26 revenue at Rs 13,815 crore, and Sky Gold and Diamonds shows the fastest revenue growth with a 67.9% compound annual rate. A useful habit with pharma, gold jewellery and hair care stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma, Gold Jewellery and Hair Care Stocks

Every theme carries risks that deserve a check before any decision. For these pharma, gold jewellery and hair care stocks, the main points are: Long-term tablet maker, ornament maker and coconut oil shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

Regulatory approvals. Plant inspections and approvals can affect supplies.
Commodity prices. Selling prices follow global and domestic markets.
Consumer spending. Sales follow festivals, incomes and consumer mood.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma, gold jewellery and hair care stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma, Gold Jewellery and Hair Care Stocks

Pharma, gold jewellery and hair care stocks work best when investors track growth, valuation and return on equity side by side. Innova Captab, Sky Gold and Diamonds and Marico each have a clear plan to grow. Based on the 11 November 2026 close, Innova Captab trades at Rs 1,092, Sky Gold and Diamonds at Rs 983.4 and Marico at Rs 925. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these pharma, gold jewellery and hair care stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track pharma, gold jewellery and hair care stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are pharma, gold jewellery and hair care stocks?

Ans. Pharma, gold jewellery and hair care stocks are listed companies that make tablets, capsules and syrups for Indian and global drug firms, manufacture gold and diamond jewellery for retailers, and sell hair oils, edible oils and personal care products. Their earnings depend on prescription demand, jewellery orders and household spending. This list looks at three of them, Innova Captab, Sky Gold and Diamonds and Marico, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which pharma, gold jewellery and hair care stocks are covered in this list?

Ans. This list covers Innova Captab, Sky Gold and Diamonds and Marico. Based on the 11 November 2026 close, Innova Captab traded at Rs 1,092, Sky Gold and Diamonds at Rs 983.4 and Marico at Rs 925. Their return on equity ranges from 12.9% to 41.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 67.9%.

Why do pharma, gold jewellery and hair care stocks have a strong future roadmap in India?

Ans. Pharma, gold jewellery and hair care stocks have a strong roadmap in India because steady demand for quality medicines, a shift to organised jewellery and rising household spending on personal care keep widening the market for these companies. The main drivers are as follows. Pharma formulations. Drug firms outsource tablets and capsules. Gold jewellery. Organised retailers source from large makers. Personal care. Households buy trusted daily brands. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

How has Sky Gold and Diamonds performed financially?

Ans. Revenue rose from Rs 796 crore in FY22 to Rs 6,331 crore in FY26, a compound annual growth rate of 67.9%. Net profit grew from Rs 133 crore in FY25 to Rs 282 crore in FY26, a rise of 112.4%. The company has a return on equity of 23.0%, a debt to equity ratio of 0.73 and a market capitalisation of Rs 14,483 crore. The stock trades at a P/E of 35.7, below the industry P/E of 44.2. Looking ahead, the company is growing its supply to organised jewellery retailers as the market shifts toward branded jewellery. Wide design capability and large-scale manufacturing support repeat orders.

How has Marico performed financially?

Ans. Revenue rose from Rs 9,610 crore in FY22 to Rs 13,815 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 1,255 crore in FY22 to Rs 1,813 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 22.2% year on year to Rs 4,005 crore, while net profit rose 27.1% to Rs 652 crore. The company has a return on equity of 41.9%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 101,286 crore. The stock trades at a P/E of 51.9, above the industry P/E of 33.9. Looking ahead, the company is widening its foods and premium personal care portfolio while strengthening its core brands. Marico also sells in Bangladesh, Vietnam and Africa, which adds international growth, and its brands command strong market share.

What risks should investors check before buying pharma, gold jewellery and hair care stocks?

Ans. Investors should check a few risks before buying pharma, gold jewellery and hair care stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Commodity prices. Selling prices follow global and domestic markets. Consumer spending. Sales follow festivals, incomes and consumer mood. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma, gold jewellery and hair care stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.